江苏诺泰澳赛诺生物制药股份有限公司的主营业务是聚焦多肽药物及小分子化药进行自主研发与定制研 发生产。公司的主要产品是定制类产品及技术服务、自主选择产品。 最新一期业绩显示，2025年一季报，公司实现营业收入5.66亿元，同比58.96%；净利润1.53亿元，同比 130.10%，销售毛利率70.20%。 7月7日，诺泰生物今日收盘37.82元，下跌3.05%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到24.36倍，总市值119.53亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均41.20倍，行业中值44.22倍，诺泰生物排 名第19位。 截至2025年一季报，共有55家机构持仓诺泰生物，其中基金48家、其他6家、社保1家，合计持股数 8271.44万股，持股市值48.78亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)3诺泰生物24.3629.564.35119.53亿行业平均 41.2048.623.50161.54亿行业中值44.2257.192.7056.99亿1药明康德17.9421.233.222005.96亿2康龙化成 22.7823.743.034 ...

Group 1 - The CRO sector experienced a slight increase of 0.13% on July 4, with a total capital outflow of 124.52 million [1] - A total of 20 stocks in the sector rose, while 18 stocks declined [1] - The top declining stocks included Bid Medicine (-3.74%), Sunshine Nuohe (-2.52%), and Chengda Pharmaceutical (-2.23%) [1][1] Group 2 - Notable stocks with significant capital outflow included Medici with a net outflow of 63.33 million and Nuo Tai Biological with a net outflow of 42.82 million [1] - Other stocks with minor fluctuations included Haoyuan Pharmaceutical (+3.26%) and Zhaoyan New Drug (+1.96%) [1][1] - The overall performance of the sector indicates mixed investor sentiment, with some stocks showing resilience while others faced notable declines [1]

Group 1: Drug Approvals and Innovations - Eli Lilly's drug Tirzepatide has received approval for a third indication in China, becoming the first and only prescription drug for treating moderate to severe obstructive sleep apnea in obese adults [1] - Diligent Pharma's innovative lung cancer drug, Shuwotai, has been granted accelerated approval by the FDA for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations [2] - Xiansheng Pharmaceutical's drug Enzashu has been approved in China as the first targeted therapy for all populations of platinum-resistant ovarian cancer, addressing a significant treatment gap in this area [3] Group 2: Financial Performance and Market Trends - Nuotai Bio expects a net profit of 300 to 330 million yuan for the first half of 2025, representing a year-on-year increase of 32.06% to 45.27%, driven by significant sales growth in peptide raw materials [4] - The recent surge in net profit forecasts from several companies, including Nuotai Bio, reflects the ongoing strong market demand for GLP-1 weight loss drugs [4] - Kangyuan Pharmaceutical's KYS2301 gel has received clinical trial approval for atopic dermatitis, marking a significant advancement in the treatment options available for this condition [5][6]

Industry News - The Ministry of Industry and Information Technology emphasizes the need to regulate low-price disorderly competition in the photovoltaic industry, guiding companies to improve product quality and promote the orderly exit of backward production capacity for sustainable development [5] - The National Medical Products Administration has announced new measures to support the innovation and development of high-end medical devices, including guidance on the registration of products based on artificial intelligence and biomaterials [7] - The National Energy Administration held a meeting to emphasize the importance of resource survey pilot work for wind and photovoltaic power generation, aiming to enhance collaboration and accelerate progress [8] - The Ministry of Commerce is set to strengthen guidance on the export of second-hand vehicles, promoting healthy and orderly development in this sector [6] Company News - Hualing Steel announced that Xintai Life Insurance has acquired a stake in the company through the secondary market [9] - Vanke A has applied for a loan of no more than 6.249 billion yuan from Shenzhen Metro Group and extended part of its existing loans [10] - Aerospace Chengtong has restored its procurement qualifications for military material engineering services [11] - Haowang Bio announced that its HW130 injection has completed Phase I clinical trials [12] - Donghu High-tech is participating in the establishment of the Donggao Frontier Phase II Fund [13] - Nuotai Bio expects a year-on-year increase of 32% to 45% in net profit attributable to shareholders for the first half of the year, driven by significant growth in sales of peptide raw materials [14] - Wealth Trend's actual controller and chairman plans to reduce his holdings by no more than 3% of the company's shares [15] - Wankai New Materials announced that some production facilities will undergo maintenance, which is expected to significantly impact the company's overall performance [16] - Huaya Intelligent stated that it is engaged in the research and production of dry electrode rolling equipment systems for solid-state batteries [17] - Changling Hydraulic announced that its controlling shareholder is planning a change of control, leading to a suspension of its stock [18] - China Power Construction signed a contract for a mining and transportation project in Guinea worth approximately 5.063 billion yuan [19]

Group 1 - The company expects a net profit attributable to shareholders of the parent company for the first half of 2025 to be between 300 million and 330 million yuan, an increase of 72.84 million to 102.84 million yuan compared to the same period last year, representing a year-on-year increase of 32.06% to 45.27% [3][5] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is also projected to be between 300 million and 330 million yuan, with a year-on-year increase of 30.78% to 43.86% [3][5] - The significant increase in profit is attributed to the company's competitive advantages in time and technology, as well as the expansion of its high-quality customer base, leading to substantial growth in sales revenue of peptide raw materials [6] Group 2 - The company completed the shareholding registration for the second vesting period of its 2023 restricted stock incentive plan, with a total of 1,232,616 shares to be listed on July 9, 2025 [12][14] - The total number of shares after the vesting will increase from 314,819,281 shares to 316,051,897 shares, without causing any change in the company's control [22][23] - The newly vested shares account for approximately 0.39% of the total shares before vesting, and are not expected to have a significant impact on the company's financial status and operating results [23]

Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for the first half of 2025 to be between 300 million yuan and 330 million yuan, representing an increase of 72.84 million yuan to 102.84 million yuan compared to the same period last year, which is a year-on-year increase of 32.06% to 45.27% [1] - The expected net profit after deducting non-recurring gains and losses is also projected to be between 300 million yuan and 330 million yuan, with similar growth compared to the previous year [1] Previous Year Performance - In the same period last year, the net profit attributable to shareholders was 227.16 million yuan, and the net profit after deducting non-recurring gains and losses was 229.39 million yuan, with a basic earnings per share of 1.06 yuan [1] Reasons for Performance Change - The company emphasizes a business philosophy of "time-leading, technology-leading" and leverages its competitive advantages in interdisciplinary collaboration and an international business development team to continuously expand its high-quality customer base, resulting in significant growth in sales revenue of peptide raw materials during the reporting period [1]

Core Viewpoint - The announcement details the implementation of the 2023 Restricted Stock Incentive Plan by Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd, including the allocation of restricted stocks and their upcoming listing date. Group 1: Stock Listing and Allocation - The total number of stocks to be listed for circulation is 1,232,616 shares, with the listing date set for July 9, 2025 [1][7]. - The stock allocation includes 62 incentive recipients, with a total of 410.8720 million shares granted, representing 30% of the total granted shares [5][6]. Group 2: Decision-Making Process - The decision-making process for the stock allocation involved multiple meetings, including the approval of the incentive plan by the board and independent directors, as well as the verification of the incentive recipient list by the supervisory board [2][3][4]. Group 3: Financial Impact - Following the stock allocation, the total share capital will increase from 314,819,281 shares to 316,051,897 shares, with the new shares accounting for approximately 0.39% of the total share capital [10][11]. - The basic earnings per share (EPS) for 2024 will be diluted, calculated based on the new total share capital, while the net profit attributable to shareholders remains unchanged at 404,389,990.70 yuan [11].

Suspension and Resumption of Trading - *ST Yazhen has completed the stock price verification and will resume trading [1] - Changling Hydraulic's actual controller is planning a major event, leading to stock suspension [1] - Shangwa New Materials' controlling shareholder is planning a major event, resulting in continued stock suspension [1] Investment Cooperation and Operational Status - Vanke A has applied for a loan of no more than 6.249 billion yuan from Shenzhen Metro Group [2] - Hualing Steel has been lifted by Xintai Life Insurance, with a shareholding ratio reaching 5% [2] - Aerospace Chenguang has restored its procurement qualifications for military material engineering services [2] - China Oil Engineering's subsidiary has won a 2.121 billion yuan project from Total Energy in Iraq [2] - Shengde Xintai has won a steel pipe procurement project from Shanghai Boiler Factory, with a bid amount of approximately 217 million yuan [2] - Xingxin New Materials plans to invest 800 million yuan to construct a project with an annual output of 153,000 tons of polyolefin and polyamine series products [2] - China Nuclear Power expects to generate 115.104 billion kilowatt-hours of electricity in the first half of 2025, a year-on-year increase of 15.92% [2] Performance Changes - Brothers Technology expects a net profit of 60 million to 70 million yuan for the first half of the year, a year-on-year increase of 325.00% to 431.25%, driven by rising prices of some vitamin products [3] - Huayin Power expects a net profit attributable to shareholders of 180 million to 220 million yuan for the half-year, an increase of 175 million to 215 million yuan compared to the same period last year [3] - Nuotai Bio expects a net profit of 300 million to 330 million yuan for the first half of 2025, a year-on-year increase of 32.06% to 45.27% [3] - Yude Development expects a net profit of 175 million to 225 million yuan for the first half of the year, compared to a loss of 32.9 million yuan in the same period last year, mainly due to the transfer of 1% equity in Langfu Company and the recognition of investment income of 240 million yuan from the fair value remeasurement of remaining equity [3]

Core Viewpoint - The article discusses the recent fluctuations in the A-share market, highlighting the impact of U.S.-Vietnam trade agreements and the performance of specific sectors, particularly consumer electronics and innovative pharmaceuticals. Market Overview - The A-share market experienced a rebound, with the Shanghai Composite Index rising by 0.18%, the Shenzhen Component Index increasing by 1.17%, and the ChiNext Index up by 1.9% [5] - The total market turnover was 13,336 billion, a decrease of 716 billion from the previous day, with over 3,200 stocks rising [5] - A total of 66 stocks hit the daily limit up, with 14 stocks achieving consecutive limit ups, the highest being six consecutive limit ups [5] Sector Performance - The consumer electronics sector saw a collective surge, with stocks like Industrial Fulian, New Asia Electronics, and Chaoyang Technology hitting the daily limit up [5] - The PCB sector also rebounded, with stocks such as Zhongjing Electronics, Bomin Electronics, and Yihua New Materials reaching the daily limit up, driven by speculation on future demand for AI-PCB [5] - Innovative pharmaceutical stocks continued their strong performance, with companies like Guosheng Tang and Changchun High-tech also hitting the daily limit up [5] Trade Policy Impact - The U.S. has lifted restrictions on EDA and ethane exports to China, while Trump announced a trade agreement with Vietnam, which will impose a 20% tariff on Vietnamese exports to the U.S. [1][2] - This policy shift is seen as beneficial for consumer electronics companies with operations in Vietnam, such as Luxshare Precision, which had previously invested in production capacity there [2] Investment Trends - Morgan Stanley's MSCI China Index has risen by 32% over the past year, indicating a recovery in consumer spending and addressing overcapacity issues [7] - The article notes that the current market environment is conducive to a potential supply-side reform, with a focus on key sectors such as automotive, materials, and technology [8][9] Capital Market Dynamics - The article highlights that despite the return to average price-to-earnings ratios, the equity risk premium remains high, suggesting that the Chinese stock market is still undervalued [9] - The low interest rates are expected to continue, with predictions of further rate cuts, which could lead to a shift in investment towards growth stocks as overall return on equity improves [9]

证券代码：688076 证券简称：诺泰生物 公告编号：2025-056 江苏诺泰澳赛诺生物制药股份有限公司 关于 2023 年限制性股票激励计划 第二个归属期归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 1,232,616股。 本次股票上市流通总数为1,232,616股。 本次股票上市流通日期为2025 年 7 月 9 日。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）于近日收到中国 证券登记结算有限责任公司上海分公司出具的《证券变更登记证明》，公司已完成 2023 年限制性股票激励计划第二个归属期的股份归属登记工作。现将相关情况公 告如下: 一、本次限制性股票归属的决策程序及相关信息披露 1、2023 年 5 月 22 日，公司召开第三届董事会第十一次会议，会议审议通过 了《关于<公司 2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于<公 司 2023 年限制性股票激励计划实施考核管理办法>的 ...